<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="t1" orientation="portrait" position="float">
 <label>Table 1</label>
 <caption>
  <title>The benefits and risks of conventional and geroprotective strategies for patients 60 or older.</title>
 </caption>
 <table frame="hsides" rules="groups">
  <col width="20%" span="1"/>
  <col width="20%" span="1"/>
  <col width="20%" span="1"/>
  <col width="20%" span="1"/>
  <col width="20%" span="1"/>
  <tbody>
   <tr>
    <td valign="middle" align="left" style="border-top: solid 1pt; border-bottom: solid 1pt" rowspan="1" colspan="1">
     <bold>Intervention</bold>
    </td>
    <td valign="middle" align="center" style="border-top: solid 1pt; border-bottom: solid 1pt" rowspan="1" colspan="1">
     <bold>Mechanism</bold>
    </td>
    <td valign="middle" align="center" style="border-top: solid 1pt; border-bottom: solid 1pt" rowspan="1" colspan="1">
     <bold>Validation</bold>
    </td>
    <td valign="middle" align="center" style="border-top: solid 1pt; border-bottom: solid 1pt" rowspan="1" colspan="1">
     <bold>Expected Benefit</bold>
    </td>
    <td valign="middle" align="center" style="border-top: solid 1pt; border-bottom: solid 1pt" rowspan="1" colspan="1">
     <bold>Side Effects and Risks</bold>
    </td>
   </tr>
   <tr>
    <td valign="middle" align="left" rowspan="1" colspan="1">
     <bold>Conventional Antiviral Strategies</bold>
    </td>
   </tr>
   <tr>
    <td valign="middle" align="left" rowspan="1" colspan="1">Vaccines</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Contains antigenic material that mounts an immune response which is then augmented on exposure to the virus and offers protection against the disease.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Major global antiviral strategy to prevent new infective cases and fight epidemics. Viral illnesses eradicated/controlled due to previous successful vaccination programs.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Vaccinated people do not develop an infection or develop a milder infection. Reduces the number of new cases and the progression of the epidemic.
     <break/>Lower effectiveness in the elderly.
    </td>
    <td valign="middle" align="center" rowspan="1" colspan="1">COVID-19 is a gerolavic infection. Efficacy of the vaccine will likely be significantly reduced due to immunosenescence and multimorbidity.
     <break/>Possible immunogenicity and mild viral prodrome symptoms as a result of vaccination.
    </td>
   </tr>
   <tr>
    <td valign="middle" align="left" rowspan="1" colspan="1">Targeted Antibodies for COVID-19</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Antibodies of serum of recovered individuals.
     <break/>Antibodies targeting specific SARS-CoV-2 proteins.
    </td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Successfully trialed in other viral diseases including Ebola.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Reduction in disease severity and lethality in exposed individuals.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Risk of systemic immune reactions and certain blood borne infections.</td>
   </tr>
   <tr>
    <td valign="middle" align="left" rowspan="1" colspan="1">Targeted Small Molecule Drugs for SARS-CoV-2</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Selective small molecule inhibitors targeting SARS-CoV-2 proteins such as 3C-like protease.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Multiple examples from Influenza. Neuraminidase and endonuclease inhibitors.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Reduction in disease duration, severity, and lethality in exposed individuals.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Mild side effects such as nausea, vomiting, diarrhea, etc.</td>
   </tr>
   <tr>
    <td valign="middle" align="left" rowspan="1" colspan="1">Symptomatic Treatments</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Non-steroidal anti-inflammatory drugs (NSAIDs), antibacterials, pain management.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Multiple clinical trials, common use.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Reduction in severity of disease.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Mild side effects such as nausea, vomiting, diarrhea, etc.</td>
   </tr>
   <tr>
    <td valign="middle" align="left" rowspan="1" colspan="1">
     <bold>Geroprotective and Senoremediation Strategies</bold>
    </td>
   </tr>
   <tr>
    <td valign="middle" align="left" rowspan="1" colspan="1">Rapalogs</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">mTOR inhibition.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Mouse, monkey, and human phase 2a studies in aging, over 95 phase 3 and phase 4 studies in humans for multiple diseases.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Infectivity: reduced; significant reduction when administered with vaccines. Severity: reduced. Lethality: reduced. Other benefits: Improved immune function that might increase the probability of increased longevity.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Risk of pancytopenia and potentially fatal infection risk.
     <break/>Risk of nephrotoxicity although milder side effect profile reported in preliminary studies.
    </td>
   </tr>
   <tr>
    <td valign="middle" align="left" rowspan="1" colspan="1">Metformin</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">mTOR inhibition.
     <break/>Mitochondrial complex 1 inhibition.
     <break/>Reduction of hepatic gluconeogenesis.
    </td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Long-term use in humans. 1
     <sup>st</sup> line treatment for type 2 diabetes, leading to weight loss and improved glucose metabolism. Improved fertility in polycystic ovarian syndrome.
    </td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Reduction in cardiovascular events, cancer, dementia, and mortality.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Diarrhea in 20% of patients.
     <break/>Contraindicated in patients with eGFR &lt;15 and reduced dose required if eGFR &lt;30 due to risk of lactic acidosis.
    </td>
   </tr>
   <tr>
    <td valign="middle" align="left" rowspan="1" colspan="1">NAD Boosters</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Sirtuin Activation.
     <break/>PARP efficacy augmentation. Improvement in cellular metabolism and repair mechanisms.
    </td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Reduction in blood pressure.
     <break/>Improvement in exercise capacity.
    </td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Reduction in immunosenescence, thus reduced infection risk and improved vaccine response. Improved endothelial function and reduced cardiovascular disease risk, potential increased lifespan.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">No increase in cellular NAD levels with supplementation and no improvement in immune function.
     <break/>Side effects of nicotinic acid include headache, skin flushing and dizziness. Uncertain effects on circulating inflammatory cytokines.
    </td>
   </tr>
   <tr>
    <td valign="middle" align="left" rowspan="1" colspan="1">Senolytics</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Reduction in anti-apoptotic senescent inactive cells. Multiple drug classes mentioned with varying disease mechanisms.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Reduced adipose tissue senescent cell burden in a short human trial.
     <break/>Improvement in pulmonary fibrosis treatment.
    </td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Reduction in senescent cell burden and thus chronic sterile inflammation; reduction of chronic disease burden.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Removal of quiescent stem cells and depletion of stem cell reserve. Drug-specific side effects. Possible elimination of pre-senescent cells leading to cardiovascular, kidney, liver, and CNS damage.</td>
   </tr>
   <tr>
    <td valign="middle" align="left" rowspan="1" colspan="1">Caloric Restriction and Intermittent Fasting</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Promotion of autophagy, metabolic flexibility.
     <break/>Increase in beta hydroxybutyrate.
    </td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Human studies showing improvement in weight, glucose levels, fasting insulin and plasma lipids that go beyond weight loss.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Activated self-defenses, reduction in body weight, improvement of insulin resistance, thus reduced cardiovascular risks and certain cancer type risks.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Sarcopenia, osteoporosis. Risk of nutritional deficiencies and worsening of eating-disorders.</td>
   </tr>
   <tr>
    <td valign="middle" align="left" rowspan="1" colspan="1">Growth Hormone (GH)</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Action via GH receptor and IGF-1 axis.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Used in humans with GH deficiency.
     <break/>Improvement in anabolic function and increase in muscle mass.
    </td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Prevention of thymus degeneration and increase in immune function. Improved mood and body composition.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Increased cancer risk. Type 2 diabetes. Connective tissue proliferation.</td>
   </tr>
   <tr>
    <td valign="middle" align="left" rowspan="1" colspan="1">FOXP3+ activation</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">One of the key mediators of immune regulation, Tregs express high levels of FOXP3. FOXP3 expression is essential for Treg development and function.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Tregs were unable to develop in a mouse receiving FOXP3-deficient progenitor cells from another animal and retroviral expression of FOXP3 in human T-cells enabled the conversion of non-regulatory na√Øve T-cells into a Treg-like phenotype.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">FOXP3 is a Treg -specific transcription factor essential for Treg functions. Rapamycin facilitates the expansion of functional CD4+CD25+FOXP3+ Treg cells.</td>
    <td valign="middle" align="center" rowspan="1" colspan="1">Treg cells are a heterogeneous population and their stability and plasticity under inflammatory conditions may pose serious problems for their clinical usage.
     <break/>No therapy yet available to modulate this cell subgroup safely in humans.
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
